Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Change in Cash (2016 - 2025)

Dexcom (DXCM) has disclosed Change in Cash for 16 consecutive years, with -$917.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Cash fell 5978.15% to -$917.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $311.8 million, a 683.42% increase, with the full-year FY2025 number at $311.8 million, up 683.42% from a year prior.
  • Change in Cash was -$917.8 million for Q4 2025 at Dexcom, down from $676.6 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $676.6 million in Q3 2025 to a low of -$917.8 million in Q4 2025.
  • A 5-year average of $5.0 million and a median of -$17.0 million in 2023 define the central range for Change in Cash.
  • Peak YoY movement for Change in Cash: skyrocketed 2862.18% in 2023, then plummeted 5978.15% in 2025.
  • Dexcom's Change in Cash stood at -$391.6 million in 2021, then soared by 85.75% to -$55.8 million in 2022, then crashed by 38.53% to -$77.3 million in 2023, then surged by 80.47% to -$15.1 million in 2024, then tumbled by 5978.15% to -$917.8 million in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Change in Cash are -$917.8 million (Q4 2025), $676.6 million (Q3 2025), and $254.2 million (Q2 2025).